Spotlight on PSMA as a new theranostic biomarker for bladder cancer
2021-01-01 Tumedei, Mm; Ravaioli, S; Matteucci, F; Celli, M; De Giorgi, U; Gunelli, R; Puccetti, M; Paganelli, G; Bravaccini, S
The current role of telomerase in the diagnosis of bladder cancer
2009-01-01 Bravaccini, S; Casadio, V; Amadori, D; Calistri, D; Silvestrini, R.
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
2021-01-01 Bravaccini, S; Bronte, G; Petracci, E; Puccetti, M; D'Arcangelo, M; Ravaioli Tumedei, Mm; Maltoni, R; Delmonte, A; Cappuzzo, F; Crinò, L
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial
2020-01-01 Bravaccini, S; Bronte, G; Scarpi, E; Ravaioli, S; Maltoni, R; Mangia, A; Tumedei, Mm; Puccetti, M; Serra, P; Gianni, L; Amaducci, L; Biglia, N; Bounous, V; Paradiso, Av; Silvestrini, R; Amadori, D; Rocca, A
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
2021-01-01 Bronte, G; Puccetti, M; Petracci, E; Landi, L; Cravero, P; Scodes, S; Ulivi, P; Ravaioli, S; Tumedei, Mm; Burgio, Ma; Cappuzzo, F; Delmonte, A; Crino, L; Bravaccini, S
The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study
2011-01-01 Sacanna, E; Ibrahim, T; Gaudio, M; Mercatali, L; Scarpi, E; Zoli, W; Serra, P; Bravaccini, S; Ricci, R; Serra, L; Amadori, D
TMB in NSCLC: A Broken Dream?
2021-01-01 Bravaccini, S; Bronte, G; Ulivi, P
Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients
2014-01-01 Rambau, P; Masalu, N; Jackson, K; Chalya, P; Serra, P; Bravaccini, S
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
2021-01-01 Bravaccini, S; Maltoni, R
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
2023-01-01 Pirini, F; Cortesi, M; Tumedei, Mm; Zanoni, M; Ravaioli, S; Bravaccini, S
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinomain situ
2020-01-01 Farolfi, A; Petracci, E; Serra, L; Ravaioli, A; Bravaccini, S; Ravaioli, S; Tumedei, Mm; Ulivi, P; Canale, M; Puccetti, M; Falcini, F; Folli, S; Curcio, A; Rocca, A
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential
2012-01-01 Calistri, D; Casadio, V; Bravaccini, S; Zoli, W; Amadori, D
Urine telomerase activity for the detection of bladder cancer in females
2007-01-01 Bravaccini, S; Sanchini, Ma; Granato, Am; Gunelli, R; Nanni, O; Amadori, D; Calistri, D; Silvestrini, R
Urine telomerase: An important marker in the diagnosis of bladder cancer
2004-01-01 Sanchini, Ma; Bravaccini, S; Medri, L; Gunelli, R; Nanni, O; Monti, F; Baccarani, Pc; Ravaioli, A; Bercovich, E; Amadori, D; Calistri, D
Usefulness of immunological detection of the human telomerase reverse transcriptase
2005-01-01 Volpi, A; Bravaccini, S; Medri, L; Cerasoli, S; Gaudio, M; Amadori, D
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
2019-01-01 Bravaccini, S
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
2020-01-01 Bravaccini, S; Martinelli, G; Cerchione, C
What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
2019-01-01 Maltoni, R; Bravaccini, S
What to look for in cell-free DNA from breast cancer patients
2018-01-01 Bronte, G; Ravaioli, S; Bravaccini, S
What's the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
2020-01-01 Bravaccini, S; Ulivi, P
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Spotlight on PSMA as a new theranostic biomarker for bladder cancer | 1-gen-2021 | Tumedei, Mm; Ravaioli, S; Matteucci, F; Celli, M; De Giorgi, U; Gunelli, R; Puccetti, M; Paganelli, G; Bravaccini, S | |
| The current role of telomerase in the diagnosis of bladder cancer | 1-gen-2009 | Bravaccini, S; Casadio, V; Amadori, D; Calistri, D; Silvestrini, R. | |
| The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects | 1-gen-2021 | Bravaccini, S; Bronte, G; Petracci, E; Puccetti, M; D'Arcangelo, M; Ravaioli Tumedei, Mm; Maltoni, R; Delmonte, A; Cappuzzo, F; Crinò, L | |
| The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial | 1-gen-2020 | Bravaccini, S; Bronte, G; Scarpi, E; Ravaioli, S; Maltoni, R; Mangia, A; Tumedei, Mm; Puccetti, M; Serra, P; Gianni, L; Amaducci, L; Biglia, N; Bounous, V; Paradiso, Av; Silvestrini, R; Amadori, D; Rocca, A | |
| The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer | 1-gen-2021 | Bronte, G; Puccetti, M; Petracci, E; Landi, L; Cravero, P; Scodes, S; Ulivi, P; Ravaioli, S; Tumedei, Mm; Burgio, Ma; Cappuzzo, F; Delmonte, A; Crino, L; Bravaccini, S | |
| The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study | 1-gen-2011 | Sacanna, E; Ibrahim, T; Gaudio, M; Mercatali, L; Scarpi, E; Zoli, W; Serra, P; Bravaccini, S; Ricci, R; Serra, L; Amadori, D | |
| TMB in NSCLC: A Broken Dream? | 1-gen-2021 | Bravaccini, S; Bronte, G; Ulivi, P | |
| Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients | 1-gen-2014 | Rambau, P; Masalu, N; Jackson, K; Chalya, P; Serra, P; Bravaccini, S | |
| Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls | 1-gen-2021 | Bravaccini, S; Maltoni, R | |
| Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota | 1-gen-2023 | Pirini, F; Cortesi, M; Tumedei, Mm; Zanoni, M; Ravaioli, S; Bravaccini, S | |
| Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinomain situ | 1-gen-2020 | Farolfi, A; Petracci, E; Serra, L; Ravaioli, A; Bravaccini, S; Ravaioli, S; Tumedei, Mm; Ulivi, P; Canale, M; Puccetti, M; Falcini, F; Folli, S; Curcio, A; Rocca, A | |
| Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential | 1-gen-2012 | Calistri, D; Casadio, V; Bravaccini, S; Zoli, W; Amadori, D | |
| Urine telomerase activity for the detection of bladder cancer in females | 1-gen-2007 | Bravaccini, S; Sanchini, Ma; Granato, Am; Gunelli, R; Nanni, O; Amadori, D; Calistri, D; Silvestrini, R | |
| Urine telomerase: An important marker in the diagnosis of bladder cancer | 1-gen-2004 | Sanchini, Ma; Bravaccini, S; Medri, L; Gunelli, R; Nanni, O; Monti, F; Baccarani, Pc; Ravaioli, A; Bercovich, E; Amadori, D; Calistri, D | |
| Usefulness of immunological detection of the human telomerase reverse transcriptase | 1-gen-2005 | Volpi, A; Bravaccini, S; Medri, L; Cerasoli, S; Gaudio, M; Amadori, D | |
| What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? | 1-gen-2019 | Bravaccini, S | |
| What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? | 1-gen-2020 | Bravaccini, S; Martinelli, G; Cerchione, C | |
| What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy? | 1-gen-2019 | Maltoni, R; Bravaccini, S | |
| What to look for in cell-free DNA from breast cancer patients | 1-gen-2018 | Bronte, G; Ravaioli, S; Bravaccini, S | |
| What's the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? | 1-gen-2020 | Bravaccini, S; Ulivi, P |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista16769
- 4 Contributo in Atti di Convegno ...2
- 2 Contributo in Volume1
Data di pubblicazione
- In corso di stampa18
- 2020 - 20278195
- 2010 - 20195973
- 2000 - 20092001
- 1990 - 1999523
- 1980 - 198961
- 1979 - 19791
Editore
- Trans Tech Publications1
Rivista
- INTERNATIONAL JOURNAL OF MOLECULA...246
- JOURNAL OF CLINICAL MEDICINE186
- CANCERS137
- INTERNATIONAL JOURNAL OF ENVIRONM...121
- DIAGNOSTICS88
- LNS. ACTIVITY REPORT85
- SCIENTIFIC REPORTS85
- PHD KORE REVIEW79
- NUTRIENTS78
- RIVISTA DELLA COOPERAZIONE GIURID...76
Serie
- ADVANCED MATERIALS RESEARCH1
- WORKING PAPERS RES1
Keyword
- COVID-19279
- Humans267
- Female142
- Male132
- SARS-CoV-2118
- inflammation111
- oxidative stress89
- Italy87
- Adult73
- Inflammation72
Lingua
- eng11972
- ita2619
- spa68
- fre66
- ger12
- lat12
- por6
- ara3
- cat3
- enm3
Accesso al fulltext
- no fulltext16772